DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Dare Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.71−0.02 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.3240 (−65.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Dare Bioscience, Inc. reported revenue of $1.37M for the twelve months to Jun 30, 2026. Free cash flow was -$11.76M.
Revenue
$1.37M
TTM Q2 2026
Operating income
-$11.11M
TTM Q2 2026
Free cash flow
-$11.76M
TTM Q2 2026
EPS, diluted
-$0.79
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.51M
- P/E ratio
- –
- Price to sales
- 7.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -111.83%
Fundamentals
- Revenue
- $1.37M
- Net income
- -$10.99M
- EPS, diluted
- -$0.79
- Free cash flow
- -$11.76M
- Book value per share
- -$0.04
- Diluted shares
- 15M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.37M
Gross profit
–
Operating income
-$11.11M
Net income
-$10.99M
EPS, diluted
-$0.79
Free cash flow
-$11.76M
Reported periodTrailing twelve months